{
    "2021-10-12": [
        [
            {
                "time": "",
                "original_text": "从“买买买”到“卖卖卖”，复星医药的“生意经”发生了啥变化？",
                "features": {
                    "keywords": [
                        "复星医药",
                        "生意经",
                        "变化"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "复星医药与赫尔森签署部分产品在中国内地及港澳地区的独家许可和分销协议",
                "features": {
                    "keywords": [
                        "复星医药",
                        "赫尔森",
                        "独家许可",
                        "分销协议"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "2020年我国医药制造业研发经费投入超700亿，百济神州最高！",
                "features": {
                    "keywords": [
                        "医药制造业",
                        "研发经费",
                        "百济神州"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星集团引入新投资者并更名为Lanvin Group",
                "features": {
                    "keywords": [
                        "复星集团",
                        "新投资者",
                        "更名",
                        "Lanvin Group"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "多元化"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "强生达雷妥尤单抗皮下注射剂型在华获批；百济泽布替尼澳大利亚获批新适应证",
                "features": {
                    "keywords": [
                        "强生",
                        "达雷妥尤单抗",
                        "百济泽布替尼",
                        "获批",
                        "新适应证"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}